among allthem are the most frequent. To cure them, usually offer surgery to remove the cancerous area, followed by a . But’ could replace this burdensome for patients. In effect, made at Memorial Sloane Kettering Cancer Center in New York gave impressive results: 100% of patients were in without the need for surgery or chemotherapy, after treatment with a therapy, dostarlimab.
Tested on a smallof twelve patients, suffering from phase II or III rectal adenocarcinoma, dostarlimab made it possible to eradicate purely and simply the after one injection every three weeks for six months. In 100% of patients, the tumor was undetectable at MRI, and in rectal. They did not need surgery or chemotherapy to complete the action of dostarlimab. No patient had a relapse during the follow-up period, which lasted from 6 to 25 months. Dostarlimab did not cause serious side effects in most patients, only rashes, fatigue, nausea, and . Only one person developed a non-life-threatening thyroid problem.
Dostarlimab also offers hope for people withof Lynch – eight among the twelve participants in the . This hereditary disease drastically increases the risk of developing colorectal cancer throughout life, and is associated with poorer outcomes after surgery or cancer chemotherapy. L’ could be a promising tool to treat patients affected by Lynch syndrome.
This approach only works on cancers of theso-called deficient mismatch system , which represent between 10 to 15% of rectal adenocarcinomas diagnosed each year. Dostarlimab is an antibody that prevents recognition of the PD-1 receptor, located on the T, with sound PDL-1, located on cancer cells. The interaction of the receptor with its ligand paralyzes the – , the T lymphocyte spares it. By mechanically blocking this interaction, dostarlimab allows T cells to destroy the abnormal cell.
Impressive results that will need to be replicated in future independent clinical trials involving more participants. The question of theresults will also be crucial; if the participants have been in remission for several months, there is nothing to say to date that they will still be in several years.